Large cohort studies have shown no increased risk compared to other metabolic medications (Douros et al., 2025)
Featured Clinical Research Sessions Featured Clinical Research I (Session 201) Saturday, March 28, Noon-1 PM CT, La Nouvelle B A Prospective Multicenter Registry to Define Coronary Vasomotor Disorders in Ischemia With Nonobstructive Coronary Arteries: Primary Results of Discover Inoca
On nutrition, because GLP-1 therapies reduce appetite significantly, ensuring adequate protein intake (discussed in the evidence as approximately 1.5 g per kg) to preserve muscle mass is a practical consideration
For Greenwood, Mooresville, or Avon residents who'd otherwise face a 40-minute drive up I-65 or I-74, telehealth is worth prioritizing
It has been available longer and costs less than tirzepatide across both brand-name and compounded options
Tirzepatide (Zepbound/Mounjaro) is a newer dual-action GIP/GLP-1 agonist that targets two hormonal pathways for even greater results
